구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Liposomal doxorubicin (Liposomal doxorubicin) Palleos Healthcare GmbH·Breast Neoplasms 130 trials·t½ 78.4 days |
|---|---|
Overview Program | Liposomal doxorubicin |
Overview Company | Palleos Healthcare GmbH |
Overview Modality | ADC |
Overview Target | Breast Neoplasms |
Overview Indication | Lymphoproliferative Disorder; HHV-8 |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | deruxtecan in a patient with metastatic human epid |
Technology Linker | cleavable sulfo-SPDB linker |
MoA Mechanism | , Clinical and Translational Science |
MoA Biomarker | biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study |
PK/PD Half-life | 78.4 days |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | interstitial lung disease was excluded, and treatment resumed with steroid cover |
Clinical Safety signal | interstitial lung disease was excluded, and treatment resumed with steroid cover |
Clinical Selected reported efficacy | 60% |
Clinical Reported PFS | 86.6 |
Clinical Reported OS | 98.3 |
Clinical Result source | ClinicalTrials.gov NCT00712582 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00712582 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Liposomal doxorubicin (Liposomal doxorubicin) Palleos Healthcare GmbH·Breast Neoplasms 130 trials·t½ 78.4 days |
|---|---|
Overview Program | Liposomal doxorubicin |
Overview Company | Palleos Healthcare GmbH |
Overview Modality | ADC |
Overview Target | Breast Neoplasms |
Overview Indication | Lymphoproliferative Disorder; HHV-8 |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | deruxtecan in a patient with metastatic human epid |
Technology Linker | cleavable sulfo-SPDB linker |
MoA Mechanism | , Clinical and Translational Science |
MoA Biomarker | biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study |
PK/PD Half-life | 78.4 days |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | interstitial lung disease was excluded, and treatment resumed with steroid cover |
Clinical Safety signal | interstitial lung disease was excluded, and treatment resumed with steroid cover |
Clinical Selected reported efficacy | 60% |
Clinical Reported PFS | 86.6 |
Clinical Reported OS | 98.3 |
Clinical Result source | ClinicalTrials.gov NCT00712582 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00712582 |
추천 비교
추천 비교